| Literature DB >> 22296783 |
Nick Kontodimopoulos1, Eleni Arvanitaki, Vassilis H Aletras, Dimitris Niakas.
Abstract
OBJECTIVES: Measurement of treatment satisfaction in diabetes is important as it has been shown to be associated with positive outcomes, reduced disease cost and better health. The aim of this study was to assess the construct validity and internal consistency reliability of the Greek version of the Diabetes Treatment Satisfaction Questionnaire (DTSQ).Entities:
Mesh:
Substances:
Year: 2012 PMID: 22296783 PMCID: PMC3292919 DOI: 10.1186/1477-7525-10-17
Source DB: PubMed Journal: Health Qual Life Outcomes ISSN: 1477-7525 Impact factor: 3.186
Sample characteristics (N = 172)
| Age (mean ± SD) | 65.2 ± 13.1 |
| Diabetes duration (mean ± SD) | 5.2 ± 4.9 |
| BMI (Kg/m2) (mean ± SD) | 31.2 ± 5.9 |
| N (%) | |
| Gender (female) | 107 (62.2) |
| Recent HbA1c level | |
| < 6.5% | 49 (28.5) |
| 6.5-7.5% | 74 (43.0) |
| > 7.5% | 49 (28.5) |
| Diabetes control method | |
| Oral agents | 137 (79.7) |
| Insulin | 35 (21.3) |
| Comorbid conditions | |
| Hyperlipidaemia | 95 (55.2) |
| Hypertension | 79 (45.2) |
| Arthropathy | 31 (18.0) |
| COPD | 15 (8.7) |
| Macrovascular heart disease | 63 (36.6) |
| Microvascular disease | 13 (7.6) |
| Diabetic foot | 11 (6.4) |
DTSQ item descriptive statistics
| Item | Description | Mean (SD) | Median | Item response distribution (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 1 | 2 | 3 | 4 | 5 | 6 | ||||
| 1 | Current treatment | 3.17 (1.03) | 3.00 | 1.2 | 4.1 | 18.0 | 39.0 | 29.1 | 8.7 | - |
| 4 | Treatment convenience | 3.00 (1.00) | 3.00 | 0.6 | 5.2 | 22.7 | 43.6 | 21.5 | 5.8 | 0.6 |
| 5 | Treatment flexibility | 2.93 (1.09) | 3.00 | 2.3 | 5.8 | 25.0 | 36.6 | 23.8 | 6.4 | - |
| 6 | Treatment understanding | 3.03 (1.07) | 3.00 | - | 7.0 | 23.8 | 38.4 | 20.3 | 10.5 | - |
| 7 | Treatment recommendation | 2.23 (1.20) | 2.00 | 7.6 | 19.8 | 31.4 | 29.1 | 8.1 | 4.1 | - |
| 8 | Treatment continuation | 3.00 (1.09) | 3.00 | 1.2 | 3.5 | 26.2 | 37.8 | 26.2 | 5.2 | - |
| DTSQ score | 17.48 (5.54) | 18.00 | ||||||||
| 2 | Perceived hyperglycaemia | 2.58 (1.48) | 2.00 | 6.4 | 20.3 | 25.0 | 18.6 | 16.3 | 13.4 | - |
| 3 | Perceived hypoglycaemia | 3.53 (1.37) | 4.00 | 1.7 | 8.1 | 14.5 | 18.0 | 26.7 | 30.2 | 0.6 |
Factor loadings, internal consistency and item-scale correlations (N = 172)
| Item | Description | Factor loadings | Internal consistency reliability1 | Item-scale correlations2 | |||
|---|---|---|---|---|---|---|---|
| Overall | Item deleted | DTSQ score | Item 2 | Item 3 | |||
| 1 | Current treatment | 0.77 | 0.92 | 0.90 | 0.76 | -0.17* | -0.26*** |
| 4 | Treatment convenience | 0.83 | 0.90 | 0.78 | -0.18* | -0.35*** | |
| 5 | Treatment flexibility | 0.74 | 0.90 | 0.73 | -0.18* | -0.32*** | |
| 6 | Treatment understanding | 0.87 | 0.89 | 0.80 | -0.08 | -0.25*** | |
| 7 | Treatment recommendation | 0.67 | 0.91 | 0.70 | -0.01 | -0.31*** | |
| 8 | Treatment continuation | 0.87 | 0.89 | 0.81 | -0.24** | -0.38*** | |
| 2 | Perceived hyperglycaemia | 0.48 | 0.78 | NA | -0.20* | - | 0.64*** |
| 3 | Perceived hypoglycaemia | 1.22 | NA | -0.38* | 0.64*** | - | |
1 Cronbach's alpha
2 Corrected for overlap
*P < 0.05, **P < 0.01, ***P < 0.001 according to Pearson's correlation
Pearson's correlations between DTSQ and SF-36 scales and summary components (N = 172)
| DTSQ items and scale1 | SF-36 scales | SF-36 components | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| PF | RP | BP | GH | VT | SF | RE | MH | PCS | MCS | |
| Current treatment (item 1) | 0.31*** | 0.29*** | 0.24*** | 0.46*** | 0.30*** | 0.33*** | 2.83*** | 0.29*** | 0.36*** | 0.32*** |
| Perceived hyperglycaemia (item 2) | -0.17* | -0.12 | 0.01 | -0.20** | -0.08 | -0.21** | -0.16* | -0.19* | -0.09 | -0.21** |
| Perceived hypoglycaemia (item 3) | -0.12 | -0.11 | -0.02 | -0.18* | -0.07 | -0.18* | -0.08 | -0.07 | -0.10 | -0.10 |
| Treatment convenience (item 4) | 0.16* | 0.12 | 0.11 | 0.36*** | 0.17* | 0.19* | 0.09 | 0.17* | 0.20** | 0.17* |
| Treatment flexibility (item 5) | 0.14 | 0.09 | 0.06 | 0.34*** | 0.13 | 0.17* | 0.15* | 0.19* | 0.14 | 0.21** |
| Treatment understanding (item 6) | 0.30*** | 0.22** | 0.21** | 0.47*** | 0.32*** | 0.32*** | 0.18* | 0.29*** | 0.33*** | 0.30*** |
| Treatment recommendation (item 7) | 0.27*** | 0.16* | 0.17* | 0.35*** | 0.26*** | 0.29*** | 0.12 | 0.24** | 0.27*** | 0.24** |
| Treatment continuation (item 8) | 0.28*** | 0.19* | 0.18* | 0.45*** | 0.31*** | 0.30*** | 0.14 | 0.29*** | 0.30*** | 0.29*** |
| Overall score (treatment satisfaction) | 0.28*** | 0.19* | 0.20** | 0.47*** | 0.27*** | 0.32*** | 0.17* | 0.28*** | 0.31*** | 0.28*** |
1 DTSQ overall satisfaction score is the sum of responses to items 1, 4, 5, 6, 7 and 8
*P < 0.05, **P < 0.01, *** P < 0.001
Abbreviations: PF - Physical Function, RP - Role Physical, BP - Bodily Pain, GH - General Health, VT - Vitality, SF - Social Functioning, RE - Role Emotional, MH - Mental Health, PCS - Physical Component Score, MCS - Mental Component Score
Perceived treatment satisfaction, hyper- and hypoglycaemia by demographic and diabetes-related variables
| Variable | N (%) | Overall Treatment | Perceived | Perceived | |||
|---|---|---|---|---|---|---|---|
| Mean | P-value | Mean | P-value | Mean | P-value | ||
| Overall | 172 (100) | 17.48 | - | 2.58 | - | 3.53 | - |
| Gender | |||||||
| Male | 65 (37.8) | 16.86 | 2.94 | 3.91 | |||
| Female | 107 (62.2) | 17.85 | 2.36 | 3.30 | |||
| Age group | |||||||
| < 55 | 33 (19.2) | 19.42 | 2.67 | 3.64 | |||
| 55-64 | 38 (22.1) | 17.95 | 2.58 | 3.47 | |||
| 65-74 | 59 (34.3) | 17.02 | 2.54 | 3.58 | |||
| ≥ 75 | 42 (24.4) | 16.17 | 2.57 | 3.43 | |||
| Years with diabetes | |||||||
| 1-3 | 86 (50.0) | 18.00 | 2.38 | 3.42 | |||
| 4-9 | 55 (32.0) | 17.42 | 2.78 | 3.58 | |||
| ≥ 10 | 31 (18.0) | 16.13 | 2.77 | 3.74 | |||
| BMI | |||||||
| 18.5-24.9 | 16 (9.3) | 17.69 | 2.25 | 3.44 | |||
| 25.0-29.9 | 70 (40.7) | 17.47 | 2.84 | 3.66 | |||
| 30.0-34.9 | 47 (27.3) | 17.06 | 2.34 | 3.57 | |||
| ≥ 35.0 | 39 (22.7) | 17.48 | 2.54 | 3.28 | |||
| HbA1c | |||||||
| < 6.5% (good) | 49 (28.5) | 20.43 | 1.53 | 2.41 | |||
| 6.5%-7.5% (fair) | 74 (43.0) | 17.31 | 2.82 | 3.86 | |||
| > 7.5% (poor) | 49 (28.5) | 14.78 | 3.27 | 4.14 | |||
| Control method | |||||||
| Oral agents | 138 (80.2) | 18.61 | 2.34 | 3.30 | |||
| Insulin1 | 34 (19.8) | 12.88 | 3.56 | 4.47 | |||
| ≥ 1 comorbidity2 | |||||||
| Yes | 135 (79.7) | 17.16 | 2.58 | 3.54 | |||
| No | 37 (20.3) | 18.65 | 2.59 | 3.49 | |||
| Coronary/vascular disease | |||||||
| Yes | 63 (36.6) | 16.07 | 2.92 | 3.71 | |||
| No | 109 (63.4) | 18.08 | 2.39 | 3.42 | |||
| ≥ 1 microvascular complication3 | |||||||
| Yes | 13 (7.6) | 17.15 | 2.62 | 3.23 | |||
| No | 159 (92.4) | 17.50 | 2.58 | 3.55 | |||
| Diabetic foot | |||||||
| Yes | 11 (6.4) | 12.55 | 3.27 | 3.73 | |||
| No | 161 (93.6) | 17.81 | 2.53 | 3.52 | |||
1 Approximately half the diabetics in this group take oral agents alongside insulin
2 Including hyperlipidaemia, hypertension, arthropathy or COPD
3 Including retinopathy, neuropathy or nephropathy
P-values derived from independent samples t-test or ANOVA
Multivariate OLS regression models
| DTSQ | Predictors | Β | SE | t | P-sig | R2 |
|---|---|---|---|---|---|---|
| Satisfaction | (Constant) | 30.976 | 2.686 | 11.532 | ||
| Gender (Female) | 0.011 | 0.765 | 0.015 | 0.988 | ||
| Age1 | -1.031 | 0.406 | -2.540 | |||
| Years therapy1 | -0.399 | 0.514 | -0.777 | 0.438 | ||
| BMI class1 | 0.019 | 0.416 | 0.045 | 0.964 | ||
| HbA1c1 | -1.874 | 0.511 | -3.668 | |||
| Control method1 | -4.586 | 0.997 | -4.601 | |||
| Comorbidity | -1.002 | 0.897 | -1.117 | 0.266 | ||
| Coronary/vascular disease | -0.340 | 0.840 | -0.405 | 0.686 | ||
| Microvascular disease | 2.398 | 1.444 | 1.661 | 0.099 | ||
| Diabetic foot | -3.190 | 1.558 | -2.047 | |||
| Perceived Hyperglycaemia | (Constant) | 0.944 | 0.740 | 1.275 | 0.204 | |
| Gender (Female) | -0.254 | 0.211 | -1.205 | 0.230 | ||
| Age1 | -0.121 | 0.112 | -1.082 | 0.281 | ||
| Years therapy1 | 0.198 | 0.142 | 1.397 | 0.164 | ||
| BMI class1 | -0.099 | 0.115 | -0.864 | 0.389 | ||
| HbA1c1 | 0.676 | 0.141 | 4.800 | |||
| Control method1 | 0.709 | 0.275 | 2.583 | |||
| Comorbidity | -0.047 | 0.247 | -0.189 | 0.851 | ||
| Coronary/vascular disease | 0.384 | 0.231 | 1.660 | 0.099 | ||
| Microvascular disease | -0.303 | 0.398 | -0.762 | 0.447 | ||
| Diabetic foot | 0.233 | 0.429 | 0.544 | 0.587 | ||
| Perceived Hypoglycaemia | (Constant) | 1.815 | 0.674 | 2.694 | ||
| Gender (Female) | -0.281 | 0.192 | -1.463 | 0.145 | ||
| Age1 | -0.077 | 0.102 | -0.757 | 0.450 | ||
| Years therapy1 | 0.202 | 0.129 | 1.569 | 0.119 | ||
| BMI class1 | -0.115 | 0.104 | -1.105 | 0.271 | ||
| HbA1c1 | 0.698 | 0.128 | 5.444 | |||
| Control method1 | 0.768 | 0.250 | 3.073 | |||
| Comorbidity | 0.043 | 0.225 | 0.190 | 0.850 | ||
| Coronary/vascular disease | 0.148 | 0.211 | 0.704 | 0.482 | ||
| Microvascular disease | -0.646 | 0.362 | -1.784 | 0.076 | ||
| Diabetic foot | -0.265 | 0.391 | -0.677 | 0.499 | ||
1 According to the groups designated in Table 5